Read Full Article from ONC LIVE
The FDA approved a ready-to-dilute thiotepa formulation for breast and ovarian cancer, enhancing treatment flexibility and reducing preparation errors.
Thiotepa, an alkylating agent approved since 1959, is now available in a 100 mg/10 mL multi-dose vial, stable for 14 days post-opening.
